Cipla, Formosa sign multi-regional licensing deal for Clobetasol Suspension

The partnership aims to enhance ophthalmic care by providing better treatment for post-operative inflammation and pain in patients across 11 countries Cipla announced an exclusive licensing agreement with Taiwan-based Formosa Pharmaceuticals for the commercialisation of clobetasol propionate ophthalmic suspension, 0.05 per cent (APP13007). Under this agreement, Cipla has exclusive rights to mark